Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of congenital nephrogenic diabetes insipidus with fluconazole
2024-517438-16-00Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluconazole in congenital arginine vasopressin resistance (cAVP-R), sponsored by University Hospital Odense. Primary endpoints: Spontaneous urinary volume and Urinary concentration ability (osmolality). Started Sep 2024; status: completed.
02
Drugs
fluconazole
03
Conditions
congenital arginine vasopressin resistance (cAVP-R)
Beyond the preview
Go deeper on 2024-517438-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517438-16-00.